Famotidine in the short and long-term treatment of duodenal ulcer.
Famotidine was compared to ranitidine in a short-term study on the treatment of duodenal ulcer. Famotidine 20 mg. b.i.d., 40 mg. b.i.d. and 40 mg. nocte heal as many ulcer as ranitidine (90.9%, 91.7%, 83.3% and 100% respectively). A single 20 mg. bedtime dose shows to be effective on preventing ulcer recurrence for as long as 48 weeks; the 38% recurrence rate observed with famotidine was statistically different from the 78% observed with placebo. Diarrhoea was the most common complain observed during the short-term trial, followed by sleepiness and headache. The few and small biochemical alterations during the long-term treatment (increase in transaminases, alkaline phosphatase, glucose, BUN) could in no instance be directly related to the substances on use.
Zaterka
S
S
Departamento de Gastroenterologia, Faculdade de Medicina da Universidade de Säo Paulo, Brazil.
de Paula Castro
L
L
Villalobos
J J
JJ
Massuda
H K
HK
Eisig
J N
JN
Dias Avelar
C
C
Coelho
L G
LG
Bettarello
A
A
D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000188:drug therapy*; D015738:Famotidine; D005260:Female; D006801:Humans; D008297:Male; D011897:Random Allocation; D011899:Ranitidine / Q000008:administration & dosage / Q000627:therapeutic use*; D013844:Thiazoles / Q000008:administration & dosage / Q000627:therapeutic use*
D000897:Anti-Ulcer Agents; D013844:Thiazoles; D015738:Famotidine; D011899:Ranitidine